ATE507822T1 - Stabilisierte zusammensetzungen von faktor-vii- polypeptiden - Google Patents

Stabilisierte zusammensetzungen von faktor-vii- polypeptiden

Info

Publication number
ATE507822T1
ATE507822T1 AT04804925T AT04804925T ATE507822T1 AT E507822 T1 ATE507822 T1 AT E507822T1 AT 04804925 T AT04804925 T AT 04804925T AT 04804925 T AT04804925 T AT 04804925T AT E507822 T1 ATE507822 T1 AT E507822T1
Authority
AT
Austria
Prior art keywords
factor vii
vii polypeptides
stabilized compositions
compositions
polypeptides
Prior art date
Application number
AT04804925T
Other languages
English (en)
Inventor
Birthe Hansen
Michael Jensen
Troels Kornfelt
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507822(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE507822T1 publication Critical patent/ATE507822T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
AT04804925T 2003-12-19 2004-12-17 Stabilisierte zusammensetzungen von faktor-vii- polypeptiden ATE507822T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301901 2003-12-19
PCT/EP2004/053587 WO2005058283A2 (en) 2003-12-19 2004-12-17 Stabilised compositions of factor vii polypeptides

Publications (1)

Publication Number Publication Date
ATE507822T1 true ATE507822T1 (de) 2011-05-15

Family

ID=34684457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04804925T ATE507822T1 (de) 2003-12-19 2004-12-17 Stabilisierte zusammensetzungen von faktor-vii- polypeptiden

Country Status (20)

Country Link
US (7) US20070021338A1 (de)
EP (4) EP3378470A1 (de)
JP (2) JP2007519623A (de)
KR (4) KR20150138427A (de)
CN (1) CN1917861B (de)
AT (1) ATE507822T1 (de)
AU (1) AU2004298789A1 (de)
BR (1) BRPI0417721B8 (de)
CA (1) CA2549593C (de)
DE (1) DE602004032573D1 (de)
DK (1) DK2298287T3 (de)
ES (1) ES2676644T3 (de)
HU (1) HUE038162T2 (de)
MX (1) MXPA06006886A (de)
PL (1) PL2298287T3 (de)
PT (1) PT2298287T (de)
RU (1) RU2373953C2 (de)
SI (1) SI2298287T1 (de)
TR (1) TR201809670T4 (de)
WO (1) WO2005058283A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
RU2357751C2 (ru) 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
EP2392655A3 (de) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Gerinnungsfaktor VII Polypeptide
KR20150138427A (ko) 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
RU2440810C2 (ru) * 2005-04-28 2012-01-27 Ново Нордиск Хелс Кеа Аг Закрытый контейнер, содержащий активированный полипептид фактора vii, способы его получения и набор и способ применения набора
AU2012213951B2 (en) * 2005-04-28 2014-10-16 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
US20070135343A1 (en) 2005-11-01 2007-06-14 Wyeth Sodium chloride solution for drug reconstitution or dilution
DE102006008613A1 (de) * 2006-02-24 2007-08-30 Dade Behring Marburg Gmbh Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
WO2008009635A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
WO2008023052A1 (en) * 2006-08-24 2008-02-28 Novo Nordisk Health Care Ag Combination of a fvii and a thrombin-activable factor x
EP2114379A2 (de) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Faktor-vi- und -viia-zusammensetzungen
EP2152233A1 (de) * 2007-05-02 2010-02-17 Novo Nordisk Health Care AG Hochkonzentrierte faktor-vii-polypeptid-formulierungen mit einem aromatischen konservierungsmittel und einem antioxidans
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
EP2385825B1 (de) * 2008-11-07 2018-10-10 University of Connecticut Faktor-viii-formulierungen
EP2453874A2 (de) * 2009-07-14 2012-05-23 Biogen Idec MA Inc. Verfahren zur hemmung von gelbfärbung und peroxidbildung bei einer zusammensetzung
EP2651433A1 (de) * 2010-12-16 2013-10-23 Novo Nordisk A/S Wässrige faktor-viii-lösung
AU2012261813B2 (en) * 2011-06-02 2017-04-20 Takeda Pharmaceutical Company Limited Formulations of recombinant furin
CN104519912A (zh) * 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
ES2926798T3 (es) * 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
CN103893135B (zh) * 2014-03-28 2017-01-11 中国医学科学院输血研究所 一种人血浆蛋白c的冻干稳定剂组合物及其用途
JP6516829B2 (ja) * 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3394095B1 (de) * 2015-12-23 2023-09-27 Phoenix Tissue Repair Inc. Kollagen-7-zusammensetzungen und verfahren zur verwendung davon
CN106139127B (zh) * 2016-08-05 2020-04-07 无锡药明生物技术股份有限公司 重组凝血因子ⅷ冻干制剂
ES3066533T3 (en) 2016-11-02 2026-05-13 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
US20200206166A1 (en) 2017-07-20 2020-07-02 Centrexion Therapeutics Corporation Methods and compositions for treatment of pain using capsaicin
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
JP7847082B2 (ja) * 2019-10-06 2026-04-16 ブリム バイオテクノロジー インク Ｐｅｄｆ由来短ペプチド（ｐｄｓｐ）を含む組成物及びその使用
EP4240757A2 (de) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Reinigung von fviii aus plasma mittels siliciumoxidadsorption
JP7371208B2 (ja) * 2022-01-19 2023-10-30 Ｋｍバイオロジクス株式会社 ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ因子含有製剤
CN116510006A (zh) * 2022-01-31 2023-08-01 拜奥卡德联合股份公司 抗trbv9抗体的药物组合物及其用途

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115590A (en) * 1871-06-06 Lfxlproxeixie
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) * 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US4404132A (en) * 1980-05-27 1983-09-13 Cutter Laboratories, Inc. Blood coagulation promoting product
CA1182748A (en) 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
EP0225160B1 (de) 1985-11-26 1991-08-21 Novo Nordisk A/S Zubereitungen und Verfahren zur Behandlung von Blutungsstörungen
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
AU607927B2 (en) 1986-06-24 1991-03-21 Nordisk Gentofte A/S A process for producing a coagulation active complex of factor viii fragments
EP0317376B2 (de) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
JP3155797B2 (ja) 1991-12-26 2001-04-16 株式会社日立製作所 過電圧自己保護型半導体装置、及び、それを使用した半導体回路
DE69333928T2 (de) * 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
US5699724A (en) * 1992-12-02 1997-12-23 Buhler Ag Cleaning and sorting bulk material
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5649959A (en) * 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5993795A (en) * 1995-11-09 1999-11-30 Takemoto Yushi Kabushiki Kaisha Protein composition derived from sesame seed and use thereof
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE19903693A1 (de) 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
SI0948358T2 (sl) 1996-12-24 2012-03-30 Biogen Idec Inc Stabilne tekoče formulacije interferona
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE19853033A1 (de) 1998-11-18 2000-05-25 Centeon Pharma Gmbh Stabilisierte Proteinzubereitung für einen Gewebekleber
CA2634663C (en) * 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
ATE310533T1 (de) * 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
DE19937218A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
JP2003507388A (ja) * 1999-08-17 2003-02-25 ノボ ノルディスク アクティーゼルスカブ 凍結乾燥したケーキの安定化
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
EP1232753B1 (de) 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
US6750053B1 (en) * 1999-11-15 2004-06-15 I-Stat Corporation Apparatus and method for assaying coagulation in fluid samples
EP1982732A3 (de) 2000-02-11 2011-06-08 Bayer HealthCare LLC Faktor VII- oder VIIA-ähnliche Konjugate
US6952212B2 (en) 2000-03-24 2005-10-04 Telefonaktiebolaget Lm Ericsson (Publ) Frame decimation for structure from motion
AU2001254624A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
EP1280548B1 (de) * 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subkutane Verabreichung des Koagulationsfaktor VII
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
SE0002960D0 (sv) 2000-08-21 2000-08-21 Eurotube Ab Engångs-smådjursfälla
HUP0301246A3 (en) 2000-09-13 2005-12-28 Novo Nordisk Healthcare Ag Human coagulation factor vii variants
EP1325127B1 (de) * 2000-10-02 2009-03-11 Novo Nordisk Health Care AG Verfahren zur herstellung vitamin-k-abhängiger proteine
AU2002218029A1 (en) * 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
EP1226829B1 (de) * 2001-01-08 2008-06-11 CSL Behring GmbH Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
IL157842A0 (en) 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
WO2003006054A1 (en) * 2001-07-10 2003-01-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
EP2042196B1 (de) 2001-10-10 2016-07-13 ratiopharm GmbH Neumodellierung und Glykokonjugation von Granulozyten-Kolonie stimulierender Faktor (G-CSF)
US6858587B2 (en) * 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
RU2357751C2 (ru) * 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
EP1458407A1 (de) * 2001-12-21 2004-09-22 Novo Nordisk A/S Flüssige zusammensetzung von modifizierten faktor-vii-polypeptiden
US7700733B2 (en) 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
WO2003092588A2 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
EP1503798B8 (de) * 2002-05-03 2012-03-14 Novo Nordisk Health Care AG Stabilisierte feste zusammensetzungen von modifizierter faktor vii
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
BRPI0311959B8 (pt) * 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
EP1549677B1 (de) 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII- ODER FVIIa-VARIANTEN MIT ERHÖHTER KOAGULATIONSWIRKUNG
AT501088A2 (de) 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
AU2004264282B2 (en) * 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
RU2440810C2 (ru) 2005-04-28 2012-01-27 Ново Нордиск Хелс Кеа Аг Закрытый контейнер, содержащий активированный полипептид фактора vii, способы его получения и набор и способ применения набора

Also Published As

Publication number Publication date
EP2298287B1 (de) 2018-04-11
KR20140093711A (ko) 2014-07-28
AU2004298789A1 (en) 2005-06-30
EP2298287A2 (de) 2011-03-23
CN1917861B (zh) 2012-03-21
BRPI0417721A (pt) 2007-04-03
EP1703899A2 (de) 2006-09-27
US20070021338A1 (en) 2007-01-25
TR201809670T4 (tr) 2018-07-23
US20090181895A1 (en) 2009-07-16
MXPA06006886A (es) 2006-09-04
KR20150138427A (ko) 2015-12-09
JP5852024B2 (ja) 2016-02-03
US20140127181A1 (en) 2014-05-08
RU2006120081A (ru) 2008-01-27
DK2298287T3 (en) 2018-07-23
SI2298287T1 (en) 2018-08-31
CN1917861A (zh) 2007-02-21
ES2676644T3 (es) 2018-07-23
EP3378470A1 (de) 2018-09-26
PT2298287T (pt) 2018-07-23
CA2549593C (en) 2014-02-11
EP1703899B1 (de) 2011-05-04
JP2013116899A (ja) 2013-06-13
HUE038162T2 (hu) 2018-09-28
EP2311437A1 (de) 2011-04-20
WO2005058283A3 (en) 2006-05-18
WO2005058283A2 (en) 2005-06-30
KR20060109950A (ko) 2006-10-23
BRPI0417721B1 (pt) 2021-01-26
PL2298287T3 (pl) 2019-02-28
EP2298287A3 (de) 2011-04-13
KR20130026498A (ko) 2013-03-13
RU2373953C2 (ru) 2009-11-27
CA2549593A1 (en) 2005-06-30
BRPI0417721B8 (pt) 2021-05-25
US8658597B2 (en) 2014-02-25
US20220054604A1 (en) 2022-02-24
US20180369347A1 (en) 2018-12-27
US20200046812A1 (en) 2020-02-13
DE602004032573D1 (de) 2011-06-16
US20160101163A1 (en) 2016-04-14
JP2007519623A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
DE602004032573D1 (de) Stabilisierte zusammensetzungen von faktor-vii-polypeptiden
DK1397492T3 (da) Modificerede og stabiliserede GDF-propeptider og deres anvendelser
DE60019458D1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
DE60233176D1 (de) Aus chaperonin-polypeptiden gebildete geordnete biologische nanostrukturen
DE60111430D1 (de) Hypochlorige säure zusammensetzung und ihre verwendungen
DE60238452D1 (de) Darstellung von Objekten durch Ausnutzung von Symmetrieeigenschaften der Objekte
TW200611910A (en) Interferon-alpha polypeptides and conjugates
BRPI0412320A (pt) uso de um agente modificador de reologia, e composições de revestimento
EA200701528A1 (ru) Новые нутрицевтические композиции
DE60322613D1 (de) Frostschutzproteine aus Basidiomyceten
ATE388990T1 (de) Wärmehärtbare anorganische ton-nanodispersionen und ihre verwendung
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил
DE60118935D1 (de) Dna & protein bindende miniatur proteine
DK1922128T3 (da) Element til reduktion af indholdet af finstøv i luften ved anvendelse af mos og/eller lav
BR0213278B1 (pt) composição vedante e seu uso.
DE60216370D1 (de) Kraftstoffzusatz und denselben enthaltende Kraftstoffzusammensetzung
DE60202519D1 (de) Fungizide zusammensetzungen auf der basis von pyridylmethylbenzamid-derivaten und propamocarb
DE602006011275D1 (de) Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
ATE391489T1 (de) Haarbehandlungszusammensetzungen
ITRM20040188A1 (it) Motore lineare e compressore lineare dello stesso.
DE602005009681D1 (de) Haarbehandlungszusammensetzungen mit einem disaccharid; einer disäure und einer ammoniumionen-quelle
WO2006089954A3 (en) Compounds for stabilizing factor vii polypeptide formulations
DE602005026565D1 (de) 5-(2,2-dimethyl-cyclopropyl)-3-methylpent-2-ennitril als geruchs- und geschmacksstoff
FR2840935B1 (fr) Element de construction en maconnerie de type poutre, tel que linteau ou similaire
DE602004009313D1 (de) Organosiliziumverbindungen und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties